Showing results (51-60 of 824) with videos related to
Sort By:
Pageof 83
Expert Review of Proteomics|November 15, 2018
The power of proteasome inhibition in multiple myelomaThomas A Guerrero-Garcia, Sara Gandolfi, Jacob P Laubach, et al.Blood|September 1, 2010
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaDharminder Chauhan, Ajita V Singh, Monette Aujay, et al.Current Hematologic Malignancy Reports|October 16, 2012
New proteasome inhibitors in myelomaPanisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.British Journal of Haematology|September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myelomaIris Breitkreutz, Marc S Raab, Sonia Vallet, et al.Blood|May 16, 2002
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.Blood|June 26, 2004
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Klaus Podar, et al.Blood Cancer Discovery|September 27, 2021
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activationAnnamaria Gulla, Eugenio Morelli, Mehmet K Samur, et al.Experimental Hematology|June 26, 2007
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma modelLaurence Catley, Teru Hideshima, Dharminder Chauhan, et al.Oncogene|November 25, 2003
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myelomaTeru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, et al.Pageof 83